Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.

Abstract: The present invention relates to compounds represented by formula (I) and pharmaceutically acceptable salts thereof that are antagonists of the bradykinin B1 receptor. These compounds are useful for the treatment of disorders associated with the bradykinin B1 pathway, in particular pain-related disorders.

Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.

Abstract: The compounds of formula (I): where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia and reperfusion.

Abstract: Tartronic acid acetalic ethers and esters of the general formula: ##STR1## are provided and are useful in treatment of bone dysmetabolism. As examples, Ra and Rb may be hydrogen, B is a C.sub.2 -C.sub.12 acyl group, R is phenyl and n is 0-12.

Abstract: Tartronic acid acetalic ethers and esters of the general formula: ##STR1## are provided and are useful in treatment of bone dysmetabolism. As examples, Ra and Rb may be hydrogen, B is a C.sub.2 -C.sub.12 acyl group, R is phenyl and n is 0-12.

Abstract: A process for the optical resolution of racemic dropropizine, carried out using L(+)tartaric acid as the optical resolution agent in aqueous medium, is described.

Abstract: Novel imidazopyridine derivatives of formula: ##STR1## wherein, R represents an alkoxyalky radical having 4-6 carbon atoms or a benzyl radical optionally substituted by a halogen atom, an alkyl or alkoxy radical having up to 3 carbon atoms,X represents hydrogen or an alkyl radical having up to 3 carbon atoms,n represents 0 or 1m represents an integer of from 2 to 5 inclusive,R.sub.1 and R.sub.2 may be the same or different and represent a saturated or unsaturated alkyl radical containing up to 4 carbon atoms or they, taken together with the adjacent nitrogen atom, may form a pyrrolidine, piperazine or homopiperazine ring which may be optionally substituted by an alkyl radical containing up to 3 carbon atoms, provided that when n is zero also m is zero and --N(R.sub.1)R.sub.2 represents the above defined piperazine or homopiperazine ring.The compounds (I) have an antihistaminic activity.

Abstract: 2-substituted 3-(2-ethoxyethyl)imidazo[4,5-b] pyridine derivatives of the formula ##STR1## wherein n is an integer of from 1 to 5 inclusiveR.sub.1 and R.sub.2 represent each a saturated or unsaturated alkyl radical containing from 1 to 4 carbon atoms or they form, together with the adjacent nitrogen atom an optionally substituted heterocyclic ring andthe corresponding non-toxic pharmaceutically acceptable acid addition salts.The compounds of formula (I) are endowed with antiallergic and antihistaminic activity.

Abstract: New alkylthiobenzimidazole derivatives are described which belong to the class of formula: ##STR1## wherein R.sub.1 and R.sub.2 each represent a 1-3 carbon atom alkyl radical or they may form with the adjacent nitrogen atom, an optionally substituted heterocyclic ring,X represents a hydrogen atom or methyl radicaln is 1 or 2R.sub.3 represents a 4-6 carbon atom alkoxyalkyl radical, a 7 or 8 carbon atom arylalkyl radical or a 5 or 6 carbon atom cycloalkyl radical with the exception that R.sub.3 may not be an arylalkyl radical when R.sub.1 and R.sub.2 each represent a 1-3 carbon atom alkyl radicalR.sub.4 and R.sub.5 may be the same or different and each represent a hydrogen atom or a 1-2 carbon atom alkyl or they, attached at the positions 5 and 6 of the benzimidazole nucleus, may form together the ring ##STR2## The compounds (I) possess interesting antihistaminic and anti-allergic activities.

Abstract: Novel benzimidazole derivatives (I) are described, of formula ##STR1## wherein A represents ##STR2## n is 0 or 1; m represents 0 or an integer of from 1 to 5 inclusive, provided that when n is 0, m represents an integer of from 2 to 5 inclusive;X represents a radical selected from the group consisting of benzyl, fluorobenzyl, alkoxyalkyl and tetrahydrofurfuryl;R.sub.1 and R.sub.2 represent each a saturated or unsaturated alkyl radical having of from 1 to 4 carbon atoms or they may form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring selected from the group consisting of pyrrolidine and piperidine, and the corresponding, non-toxic, pharmaceutically acceptable acid addition salts.The compounds (I) are endowed with an interesting antihistaminic activity.

Abstract: New alkylol derivatives are described, which belong to the class having the structure formula ##STR1## where R represents a 5 or 6 membered heterocyclic ring selected among pyridine, pyrimidine, pyrazine, pyridazine, thiophene, furan, thiazole which optionally may be substituted with one or more groups selected among alkyl, alkoxy, halogen, amide, hydroxy, methylthio, trifluoromethyl, cyano, carboxy and the corresponding alkyl esters and salts with alkali metalsn is 2X and X' represent each a hydrogen atom or hydroxy group with the exception of both being hydrogen atom, and X' may be hydroxyethoxy moietym is 0 or 1and the corresponding non-toxic pharmaceutically acceptable acid addition salts. The compounds of the formula I are endowed with an interesting antitussive activity and, at their active dose, practically they are free of undesired side effects.

Abstract: The present invention refers to an improved method for the preparation of 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one in which the condensation between 2-chloronicotinic acid and o-phenylenediamine is carried out by refluxing in the presence of a solvent consisting of a cycloalkanol. The end product is in pure state and it may be utilized as such.

Abstract: The optical isomers of 3-(4-phenyl-1-piperazinyl)-1,2-propanediol, a process for the stereo-selective preparation and pharmaceutical composition containing the same as active principles are described.

Abstract: The optical isomers of 3-(4-phenyl-1-piperazinyl)-1,2-propanediol, a process for the stereo-selective preparation and pharmaceutical composition containing the same as active principles are described.

Abstract: Compounds of the formula I ##STR1## wherein the A ring represents ##STR2## R.sub.1 and R.sub.2 are H or CH.sub.3 ; M is a cyclic amino group, are endowed with antiulcer, antisecretory, antimuscarinic and spasmolytic activity.

Abstract: Quaternary salts of 11-acyl derivatives of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one, 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one and 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one are described.Said quaternary salts are endowed with antiulcer, antisecretory, spasmolytic and antimuscarinic activity.